Search results for the GEO ID: GSE11237  |
(Click on the check boxes provided under "Select for analysis", to initiate grouping) |
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down) |
|
GSM ID | GPL ID |
Select for analysis |
Title |
Source name |
Description |
Characteristics |
GSM283127 | GPL8300 |
|
CRC_celecoxib_M4858
|
Celecoxib_#4858
|
Gender: Male
AJCC Stage: IV
Pathological T: 3
Pathological N: 1
Pathological M: 1
Grade: moderate
Tumor Site: Sigmoid
Drug Treatment: YES
|
4858
|
| Sample_geo_accession | GSM283127
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283127/suppl/GSM283127_5392.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283128 | GPL8300 |
|
CRC_nodrug_F4860
|
No_drug_#4860
|
Gender: Female
AJCC Stage: III
Pathological T: 3
Pathological N: 1
Pathological M: 0
Grade: poor
Tumor Site: Cecum
Drug Treatment: NO
|
4860
|
| Sample_geo_accession | GSM283128
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283128/suppl/GSM283128_5394.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283129 | GPL8300 |
|
CRC_celecoxib_M4867
|
Celecoxib_#4867
|
Gender: Male
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Cecum
Drug Treatment: YES
|
4867
|
| Sample_geo_accession | GSM283129
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283129/suppl/GSM283129_5401.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283130 | GPL8300 |
|
CRC_nodrug_M4868
|
No_drug_#4868
|
Gender: Male
AJCC Stage: III
Pathological T: 3
Pathological N: 1
Pathological M: 0
Grade: moderate
Tumor Site: Rectosigmoid
Drug Treatment: NO
|
4868
|
| Sample_geo_accession | GSM283130
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283130/suppl/GSM283130_5402.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283131 | GPL8300 |
|
CRC_nodrug_M4870
|
No_drug_#4870
|
Gender: Male
AJCC Stage: II
Pathological T: 4
Pathological N: 0
Pathological M: 0
Grade: poor
Tumor Site: Hepatic Flexure
Drug Treatment: NO
|
4870
|
| Sample_geo_accession | GSM283131
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283131/suppl/GSM283131_5403.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283132 | GPL8300 |
|
CRC_celecoxib_F4871
|
Celecoxib_#4871
|
Gender: Female
AJCC Stage: I
Pathological T: 2
Pathological N: 0
Pathological M: 0
Grade: well
Tumor Site: Sigmoid
Drug Treatment: YES
|
4871
|
| Sample_geo_accession | GSM283132
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283132/suppl/GSM283132_5404.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283133 | GPL8300 |
|
CRC_nodrug_F4872
|
No_drug_#4872
|
Gender: Female
AJCC Stage: I
Pathological T: 2
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Cecum
Drug Treatment: NO
|
4872
|
| Sample_geo_accession | GSM283133
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283133/suppl/GSM283133_5405.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283134 | GPL8300 |
|
CRC_celecoxib_F4873
|
Celecoxib_#4873
|
Gender: Female
AJCC Stage: III
Pathological T: 3
Pathological N: 1
Pathological M: 0
Grade: moderate
Tumor Site: Ascending
Drug Treatment: YES
|
4873
|
| Sample_geo_accession | GSM283134
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283134/suppl/GSM283134_5406.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283135 | GPL8300 |
|
CRC_celecoxib_F4874
|
Celecoxib_#4874
|
Gender: Female
AJCC Stage: IV
Pathological T: 3
Pathological N: 0
Pathological M: 1
Grade: well
Tumor Site: Hepatic Flexure
Drug Treatment: YES
|
4874
|
| Sample_geo_accession | GSM283135
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283135/suppl/GSM283135_5407.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283136 | GPL8300 |
|
CRC_celecoxib_M4875
|
Celecoxib_#4875
|
Gender: Male
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: moderate to poor
Tumor Site: Descending
Drug Treatment: YES
|
4875
|
| Sample_geo_accession | GSM283136
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283136/suppl/GSM283136_5408.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283137 | GPL8300 |
|
CRC_nodrug_M4876
|
No_drug_#4876
|
Gender: Male
AJCC Stage: I
Pathological T: 2
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Cecum
Drug Treatment: NO
|
4876
|
| Sample_geo_accession | GSM283137
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283137/suppl/GSM283137_5409.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283138 | GPL8300 |
|
CRC_celecoxib_M4877
|
Celecoxib_#4877
|
Gender: Male
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: poor
Tumor Site: Cecum
Drug Treatment: YES
|
4877
|
| Sample_geo_accession | GSM283138
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283138/suppl/GSM283138_5410.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283139 | GPL8300 |
|
CRC_nodrug_F4879
|
No_drug_#4879
|
Gender: Female
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: well
Tumor Site: Ascending
Drug Treatment: NO
|
4879
|
| Sample_geo_accession | GSM283139
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283139/suppl/GSM283139_5411.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283140 | GPL8300 |
|
CRC_nodrug_F4881
|
No_drug_#4881
|
Gender: Female
AJCC Stage: IV
Pathological T: 3
Pathological N: 2
Pathological M: 1
Grade: moderate
Tumor Site: Sigmoid
Drug Treatment: NO
|
4881
|
| Sample_geo_accession | GSM283140
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283140/suppl/GSM283140_5413.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283141 | GPL8300 |
|
CRC_nodrug_F4882
|
No_drug_#4882
|
Gender: Female
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Sigmoid
Drug Treatment: NO
|
4882
|
| Sample_geo_accession | GSM283141
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283141/suppl/GSM283141_5414.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283142 | GPL8300 |
|
CRC_celecoxib_F4859
|
Celecoxib_#4859
|
Gender: Female
AJCC Stage: I
Pathological T: 1
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Ascending
Drug Treatment: YES
|
4859
|
| Sample_geo_accession | GSM283142
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283142/suppl/GSM283142_5440.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283143 | GPL8300 |
|
CRC_nodrug_M4865
|
No_drug_#4865
|
Gender: Male
AJCC Stage: IV
Pathological T: 4
Pathological N: 1
Pathological M: 1
Grade: moderate
Tumor Site: Ascending
Drug Treatment: NO
|
4865
|
| Sample_geo_accession | GSM283143
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283143/suppl/GSM283143_5441.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283144 | GPL8300 |
|
CRC_nodrug_F4863
|
No_drug_#4863
|
Gender: Female
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Sigmoid
Drug Treatment: NO
|
4863
|
| Sample_geo_accession | GSM283144
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283144/suppl/GSM283144_5442.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283145 | GPL8300 |
|
CRC_celecoxib_M4861
|
Celecoxib_#4861
|
Gender: Male
AJCC Stage: III
Pathological T: 3
Pathological N: 1
Pathological M: 0
Grade: moderate
Tumor Site: Cecum
Drug Treatment: YES
|
4861
|
| Sample_geo_accession | GSM283145
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283145/suppl/GSM283145_5443.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283146 | GPL8300 |
|
CRC_nodrug_F4862
|
No_drug_#4862
|
Gender: Female
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Rectosigmoid
Drug Treatment: NO
|
4862
|
| Sample_geo_accession | GSM283146
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283146/suppl/GSM283146_5444.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283147 | GPL8300 |
|
CRC_celecoxib_F4880
|
Celecoxib_#4880
|
Gender: Female
AJCC Stage: IV
Pathological T: 4
Pathological N: 0
Pathological M: 1
Grade: moderate
Tumor Site: Sigmoid
Drug Treatment: YES
|
4880
|
| Sample_geo_accession | GSM283147
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283147/suppl/GSM283147_5445.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283148 | GPL8300 |
|
CRC_celecoxib_M4866
|
Celecoxib_#4866
|
Gender: Male
AJCC Stage: IV
Pathological T: 3
Pathological N: 1
Pathological M: 1
Grade: moderate
Tumor Site: Ascending
Drug Treatment: YES
|
4866
|
| Sample_geo_accession | GSM283148
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283148/suppl/GSM283148_5446.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
GSM283149 | GPL8300 |
|
CRC_nodrug_F4864
|
No_drug_#4864
|
Gender: Female
AJCC Stage: II
Pathological T: 3
Pathological N: 0
Pathological M: 0
Grade: moderate
Tumor Site: Cecum
Drug Treatment: NO
|
4864
|
| Sample_geo_accession | GSM283149
| | Sample_status | Public on Aug 21 2008
| | Sample_submission_date | Apr 22 2008
| | Sample_last_update_date | Mar 16 2009
| | Sample_type | RNA
| | Sample_channel_count | 1
| | Sample_organism_ch1 | Homo sapiens
| | Sample_taxid_ch1 | 9606
| | Sample_biomaterial_provider_ch1 | Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)
| | Sample_treatment_protocol_ch1 | Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study. The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.
| | Sample_molecule_ch1 | total RNA
| | Sample_extract_protocol_ch1 | Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).
| | Sample_label_ch1 | biotin
| | Sample_label_protocol_ch1 | standard Affymetrix protocol
| | Sample_hyb_protocol | standard Affymetrix protocol
| | Sample_scan_protocol | standard Affymetrix protocol
| | Sample_data_processing | Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor. Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.
| | Sample_platform_id | GPL8300
| | Sample_contact_name | James,Todd,Auman
| | Sample_contact_email | jtauman@email.unc.edu
| | Sample_contact_phone | (919) 966-9942
| | Sample_contact_department | Institute for Pharmacogenomics and Individualized Therapy
| | Sample_contact_institute | University of North Carolina at Chapel Hill
| | Sample_contact_address | 3304 Kerr Hall, Campus Box 7360
| | Sample_contact_city | Chapel Hill
| | Sample_contact_state | NC
| | Sample_contact_zip/postal_code | 27599-7360
| | Sample_contact_country | USA
| | Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM283nnn/GSM283149/suppl/GSM283149_5447.CEL.gz
| | Sample_series_id | GSE11237
| | Sample_data_row_count | 12625
| | |
|
| |
| |
Make groups for comparisons |
(2 groups will be compared at a time) |
|
| Select GSMs and click on "Add groups" |
Enter the group name here: |
|
|
|
